Drug intelligence / Profile preview

metronidazole + diltiazem

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Topical

Overview

Metronidazole + diltiazem is a combination therapy used primarily for the treatment of acute anal fissures. This combination leverages the calcium channel blocking properties of diltiazem to relax smooth muscles in the anal sphincter, while metronidazole provides antimicrobial activity against anaerobic bacteria that may cause subclinical infection in the anal fissure region. Clinical studies have shown that this combination therapy provides more rapid pain relief, improved healing rates, and reduced need for surgery compared to diltiazem alone.

Targets

CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)CACNG1 (Voltage-dependent calcium channel gamma-1 subunit)

Beyond the preview

Go deeper on metronidazole + diltiazem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + diltiazem.

Explore the full profile